FDA warning letters to foreign manufacturers jump 40%; Novartis turns to CMO to meet demands;

> The FDA sent 52 GMP warning letters in the last 12 months, and 40% of those were to manufacturing plants outside the U.S. Story

> Novartis ($NVS) is using some contract manufacturing operations to help it meet drug demands while its plant in Nebraska continues remediation. Story

> The FDA has sent letters to more than four dozen doctors and medical practices in the U.S. warning them they may have purchased counterfeit Avastin, which, if used, could harm patients. Story

> Spectrum Pharmaceuticals ($SPPI) says it has increased its manufacturing capacity for cancer treatment Fusilev (levoleucovorin) for injection. Item

> Novasep, which makes pharma purification systems, has named Jean-Claude Romain director of quality and placed him on the company's executive committee. Release

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.